Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
- Registration Number
- NCT00678392
- Lead Sponsor
- Pfizer
- Brief Summary
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 723
- Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis
- Evidence of measurable disease
- Must have failed one prior systemic first-line regimen for metastatic renal cell cancer
- Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy
- Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Axitinib Axitinib (AG-013736) - Sorafenib Sorafenib -
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) From initiation of treatment up to follow-up period (up to 3 years) PFS was defined as the time in months from start of study treatment to the first documentation of objective tumor progression of disease (PD) or to death due to any cause, whichever occurs first. PD was assessed by response evaluation criteria in solid tumors (RECIST) version 1.0. PD: \>=20 percent (%) increase in the sum of the longest dimensions (LD) of the target lesions taking as a reference the smallest sum of the LD recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. Occurrence of a pleural effusion or ascites was also considered PD if demonstrated by cytological investigation and it was not previously documented. New bone lesions not previously documented were considered PD if confirmed by computed tomography/magnetic resonance imaging or X-ray.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) From initiation of treatment up to follow-up period (up to 3 years) OS was defined as the duration from start of study treatment to date of death due to any cause. OS was calculated as (months) = (date of death minus the date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored on last date the participants were known to be alive.
Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698) FKSI-DRS was used to assess quality of life for those diagnosed with renal cell cancer and consisted of 9 items (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, and hematuria). Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher scores indicate greater presence of symptoms.
Objective Response Rate (ORR) From initiation of treatment up to follow-up period (up to 3 years) ORR = percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.0 recorded from first dose of study treatment until PD or death due to any cause. CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks. PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions. PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Duration of Response (DR) From initiation of treatment up to follow-up period (up to 3 years) DR: time from first documentation of objective tumor response (CR or PR), that was subsequently confirmed, to the first documentation of PD or to death due to any cause, whichever occurred first as per RECIST version 1.0, a) CR: disappearance of all target, non target lesions and no appearance of new lesions, documented on 2 occasions separated by at least 4 weeks, b) PR: at least 30 % decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non target lesions, no appearance of new lesions, c) PD: \>=20% increase in sum of LD of the target lesions taking as a reference smallest sum of LD recorded since the start of treatment or unequivocal progression in non-target lesions or appearance of 1 or more new lesions. Occurrence of pleural effusion or ascites if demonstrated by cytological investigation, not previously documented. New bone lesions not previously documented if confirmed by computed tomography/magnetic resonance imaging or X-ray.
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From initiation of treatment up to follow-up period (up to 3 years) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life- threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.
Percentage of Participants With Adverse Events (AEs) by Severity From initiation of treatment up to follow-up period (up to 3 years) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening or disabling; Grade 5= death related to AE.
Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) From initiation of treatment up to follow-up period (up to 3 years) An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non -serious AEs.
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology From initiation of treatment up to follow-up period (up to 3 years) Hematology laboratory test included hemoglobin, platelet count, white blood cells count, neutrophils and lymphocytes. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry From initiation of treatment up to follow-up period (up to 3 years) Biochemistry laboratory test included parameters: alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, hypophosphatemia and lipase. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis From initiation of treatment up to follow-up period (up to 3 years) Urinalysis included urine blood/ hemoglobin, glucose and protein. Abnormalities were assessed by CTCAE Grade Version 2 for severity: Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698) FKSI was used to assess quality of life (QoL) for those diagnosed with renal cell cancer and consisted of 15 items (lack of energy, side effects, pain, losing weight, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria and sleep). Each of the 15 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score = sum of the 15 item scores; total range: 0 - 60; 0 (no symptoms) to 60 (very much); higher scores indicate greater presence of symptoms.
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698) EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Health state profile component assesses level of health for 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain was rated on a 3-point response scale (1= no problems, 2= some/moderate problems and 3= extreme problems). Scoring formula developed by EuroQol Group assigned a utility value for each domain in the profile. Score were transformed and resulted in a total score range of 0 to 1, with higher scores indicating better health.
Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS) Baseline (Predose on Cycle 1 Day 1) , Day 1 of each cycle until Cycle 21, End of treatment (Day 670) and Follow-up visit (Day 698) EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. VAS component: participants rated their current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (234)
LAC-USC Medical Center
🇺🇸Los Angeles, California, United States
Ronald Regan UCLA Medical Center
🇺🇸Los Angeles, California, United States
USC Norris Cancer Hospital and Clinics
🇺🇸Los Angeles, California, United States
Metropolitan Hematology/Oncology Medical Group
🇺🇸Los Angeles, California, United States
James Care in Kenny
🇺🇸Columbus, Ohio, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Virginia Mason Medical Center, Section of Hematology/Oncology
🇺🇸Seattle, Washington, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
University of Miami Hospital and Clinics
🇺🇸Miami, Florida, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Nevada Cancer Institute
🇺🇸Las Vegas, Nevada, United States
Genitourinary Cancer Center
🇺🇸Houston, Texas, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Dr. H. Bliss Murphy Cancer Centre
🇨🇦St. John's, Newfoundland and Labrador, Canada
Sun Yet-Sen University Cancer Center
🇨🇳Guangzhou, China
Bhagwan Mahaveer Cancer Hospital and Research Center
🇮🇳Jaipur, Rajasthan, India
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
University of Minnesota Medical Center Fairview
🇺🇸Minneapolis, Minnesota, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
Unita' Operativa Oncologia Medica 2, Regione del Veneto
🇮🇹Padova, Italy
Struttura Complessa di Oncologia Medica A
🇮🇹Roma, Italy
IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
UO di Oncologia ed Ematologia, Istituto Clinico Humanitas
🇮🇹Rozzano (MI), Italy
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
Beijing Cancer Hospital
🇨🇳Beijing, P.R., China
Centre Leon Berard
🇫🇷Lyon, Cedex 08, France
Heidelberg Repatriation Hospital, Austin Health
🇦🇺Heidelberg West, Victoria, Australia
The Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital
🇨🇳Nanjing, Jiangsu, China
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Peter MacCallum Cancer Centre
🇦🇺East Melbourne, Victoria, Australia
Universitaets-Klinik fuer Innere Medizin I
🇦🇹Wien, Austria
Austin Hospital, Austin Health
🇦🇺Heidelberg, Victoria, Australia
Clinica Oncologistas Associados
🇧🇷Rio de Janeiro, RJ, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita
🇧🇷Porto Alegre, RS, Brazil
Med. Abt. KH Barmherzige Brueder Wien, Krankenhaus der Barmherzigen Brueder Wien
🇦🇹Wien, Austria
"Theagenio"Cancer Hospital / 3rd. Dept. of Clinical Oncology
🇬🇷Thessaloniki, Macedonia, Greece
CHRU de Tours - Hopital Bretonneau
🇫🇷Tours Cedex 1, France
Klinikum der Johannes-Gutenberg-Universitaet, III. Medizinische Klinik und Poliklinik
🇩🇪Mainz, Germany
Centre Alexis Vautrin
🇫🇷Vandoeuvre les Nancy, France
Innere Klinik und Poliklinik fuer Tumorforschung, Universitaetsklinikum Essen
🇩🇪Essen, Germany
Institut Gustave Roussy / Service d'Immunotherapie
🇫🇷Villejuif Cedex, France
RWTH Aachen, Urologische Klinik
🇩🇪Aachen, Germany
Klinikum Oldenburg gGmbH, Klinik fuer Innere Medizin II Onkologie / Haematologie
🇩🇪Oldenburg, Germany
UOC Oncologia Medica, Ospedale San Donato
🇮🇹Arezzo, Italy
Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS
🇮🇹Aviano (PN), Italy
Fortis Memorial Research Institute
🇮🇳Gurgaon, Haryana, India
Amrita Institute of Medical Sciences
🇮🇳Kochi, Kerala, India
Dipartimento dei laboratori diagnositici e per le terapie cellulari
🇮🇹Aviano (PN), Italy
University of Tsukuba, Graduate School of Comprehensive Human Sciences, Department of Urology
🇯🇵Tsukuba, Ibaraki, Japan
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Tokyo Women's Medical University Medical Center East, Department of Urology
🇯🇵Arakawa-ku, Tokyo, Japan
Centrum Medyczne HCP
🇵🇱Poznan, Wielkopolska, Poland
Istituto per lo Studio e la Cura dei Tumori Fondazione Pascale
🇮🇹Napoli, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
Tokushima University
🇯🇵Tokushima, Japan
Divisione di Oncologia, AORN Antonio Cardarelli
🇮🇹Napoli, Italy
Shizuoka Cancer Center
🇯🇵Sunto-gun, Shizuoka, Japan
Azienda Ospedaliera San Camillo Forlanini, Oncologia Medica, Padiglione Flajani, I piano
🇮🇹Roma, Italy
Sapporo Medical University School of Medicine
🇯🇵Sapporo-shi, Hokkaido, Japan
Azienda Ospedaliera Spedali Civili di Brescia, Unita' Operativa Oncologia Medica
🇮🇹Brescia, Italy
Struttura Complessa di Oncologia
🇮🇹Cremona, Italy
UOC Oncologia Medica B, IRCCS AO Universitaria San Martino
🇮🇹Genova, Italy
Fondazione IRCCS, Istituto Nazionale dei Tumori, SC Oncologia Medica 2
🇮🇹Milano, Italy
Tokyo Women's Medical University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
Wojewodzkie Centrum Onkologii
🇵🇱Gdansk, Poland
Yamaguchi University Hospital
🇯🇵Ube-shi, Yamaguchi, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Klinika Onkologii, Wojskowy Instytut Medyczny
🇵🇱Warszawa, Poland
Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia
🇷🇺Obninsk, Kaluga Region, Russian Federation
Akita University Hospital
🇯🇵Akita, Japan
Hospital Vall D¿Hebron
🇪🇸Barcelona, Spain
Institut Catala D'Oncologia L'Hospitalet
🇪🇸L'hospitalet de Llobregat, Barcelona, Spain
Clinica Universitaria de Navarra
🇪🇸Pamplona, Navarra, Spain
Taichung Veterans General Hospital, Department of Surgery
🇨🇳Taichung, Taiwan
Hospital de Navarra
🇪🇸Pamplona, Navarra, Spain
Clatterbridge Centre for Oncology NHS Foundation Trust
🇬🇧Bebington, Wirral, United Kingdom
Hospital Universitario Ramon Y Cajal
🇪🇸Madrid, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Weisberg Cancer Treatment Center
🇺🇸Farmington Hills, Michigan, United States
East Valley Hematology and Oncology Medical Group
🇺🇸Burbank, California, United States
Agajanian Institute of Oncology and Hematology
🇺🇸Whittier, California, United States
Los Angeles Hematology/Oncology Medical Group
🇺🇸Los Angeles, California, United States
Maurice Berkowtiz, MD
🇺🇸Burbank, California, United States
Kenmar Research Institute
🇺🇸Los Angeles, California, United States
Rocky Mountain Cancer Centers
🇺🇸Thornton, Colorado, United States
University of Colorado Denver: Division of Medical Oncology
🇺🇸Aurora, Colorado, United States
Rocky Mountain Cancer Centers, LLP
🇺🇸Denver, Colorado, United States
Georgetown University Hospital, Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Georgetown University Medical Center
🇺🇸Washington, District of Columbia, United States
University of Miami Sylvester at Deerfield Beach
🇺🇸Deerfield Beach, Florida, United States
Mountain States Tumor Institute
🇺🇸Twin Falls, Idaho, United States
Cental Indiana Cancer Centers
🇺🇸Greenfield, Indiana, United States
Central Indiana Cancer Centers
🇺🇸Indianapolis, Indiana, United States
Missouri Cancer Associates
🇺🇸Columbia, Missouri, United States
St. John's Mercy, David C. Pratt Cancer Center
🇺🇸Saint Louis, Missouri, United States
St. John's Mercy Medical Center
🇺🇸Washington, Missouri, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
The Cancer Center at Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc.
🇺🇸Oneida, New York, United States
Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Suny Upstate Medical University
🇺🇸Syracuse, New York, United States
Investigational Chemotherapy Services
🇺🇸Durham, North Carolina, United States
Raleigh Hematology Oncology Associates, DBA
🇺🇸Cary, North Carolina, United States
Virginia Oncology Associates
🇺🇸Virginia Beach, Virginia, United States
Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc
🇺🇸Syracuse, New York, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Case Western Reserve University
🇺🇸Cleveland, Ohio, United States
Ohio State University
🇺🇸Columbus, Ohio, United States
Lake University - Ireland Cancer Center (LUICC)
🇺🇸Mentor, Ohio, United States
UHHS - Chagrin Highlands
🇺🇸Orange Village, Ohio, United States
UHHS - Westlake
🇺🇸Westlake, Ohio, United States
Oncology Associates of Oregon, P.C.
🇺🇸Eugene, Oregon, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Willamette Valley Cancer Institute and Research Center
🇺🇸Springfield, Oregon, United States
Cancer Centers of the Carolinas
🇺🇸Spartanburg, South Carolina, United States
Penn State Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
Hematology and Oncology Associates of SC, LLC - Eastside Medical Center
🇺🇸Greenville, South Carolina, United States
Cancer Centers of the Carolinas, Seneca
🇺🇸Seneca, South Carolina, United States
Tennessee Oncology, PLLC
🇺🇸Smyrna, Tennessee, United States
Vanderbilt-Ingram Cancer Center-Cool Springs
🇺🇸Franklin, Tennessee, United States
Chattanooga Oncology & Hematology Associates
🇺🇸Hixson, Tennessee, United States
Texas Oncology, P.A.
🇺🇸Tyler, Texas, United States
Texas Oncology - Cedar Park
🇺🇸Cedar Park, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Investigation Products Center (IPC)
🇺🇸Fort Worth, Texas, United States
US Oncology Research and Clinical Pharmacy
🇺🇸Fort Worth, Texas, United States
Deke Slayton Cancer Center
🇺🇸Webster, Texas, United States
Texas Oncology - Round Rock
🇺🇸Round Rock, Texas, United States
Texas Oncology - Seton Williamson
🇺🇸Round Rock, Texas, United States
Texas Oncology - Clear Lake
🇺🇸Webster, Texas, United States
The Canberra Hospital, Medical Oncology
🇦🇺Garran, Australian Capital Territory, Australia
Virginia Cancer Specialists, PC
🇺🇸Woodbridge, Virginia, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Ashford Cancer Centre Research
🇦🇺Kurralta Park, South Australia, Australia
Ballarat Oncology & Haematology Services
🇦🇺Ballarat, Victoria, Australia
Fundacao Antonio Prudente
🇧🇷Sao Paulo, SP, Brazil
British Columbia Cancer Agency - Cancer Centre for the Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Dr. Leon Richard Oncology Centre
🇨🇦Moncton, New Brunswick, Canada
RSM Durham Regional Cancer Centre Lakeridge Health Oshawa
🇨🇦Oshawa, Ontario, Canada
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, Chaoyang District, China
Xijing Hospital, The Fourth Military Medical University
🇨🇳Xi'an, Shaanxi, China
Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Tianjin Oncology Hospital,biology treatment department
🇨🇳Tianjin, China
Hopital Europeen Georges Pompidou
🇫🇷Paris Cedex 15, France
Hôpital Henri Mondor
🇫🇷CRETEIL Cedex, France
Hopital Saint-André
🇫🇷Bordeaux Cedex, France
Institut Paoli-Calmettes
🇫🇷Marseille Cedex 09, France
Centre Eugene Marquis
🇫🇷Rennes, France
Centre Rene Gauducheau - Service Oncologie Medicale
🇫🇷St Herblain Cedex, France
Klinikum Region Hannover Krankenhaus Siloah
🇩🇪Hannover, Germany
Alexandra University Hospital / Oncology Dept.
🇬🇷Athens, Attiki, Greece
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Hamamatsu University School of Medicine
🇯🇵Hamamatsu-City, Shizuoka, Japan
Kinki University Hospital
🇯🇵Osakasayama, Osaka, Japan
National Cancer Center Hospital
🇯🇵Chuo-Ku, Tokyo, Japan
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
Keio University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
National Cancer Center, Urologic Oncology Clinic, Center for Specific Organs Cancer
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Dong-A University Medical Center, Department of Medicine, Division of Hemato-Oncology
🇰🇷Busan, Korea, Republic of
Norrlands Universitetssjukhus, Onkologkliniken
🇸🇪Umea, Sweden
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Catholic University of Korea, Seoul St. Mary's Hospital, Department of Oncology
🇰🇷Seoul, Korea, Republic of
Wielkopolskie Centrum Onkologii im.Marii Sklodowskiej-Curie
🇵🇱Poznan, Wielkopolska, Poland
Klinika Onkologii, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego
🇵🇱Poznan, Poland
Klinika Urologii i Onkologii Urologicznej
🇵🇱Wroclaw, Poland
Cancer Research Center named after N.N.Blokhin, Chemotherapy Department
🇷🇺Moscow, Russian Federation
Russian Research Center of Roentgenology and Radiology
🇷🇺Moscow, Russian Federation
Cancer Research Center named after N.N. Blokhin, Biotherapy Department
🇷🇺Moscow, Russian Federation
The Main Clinical Hospital of the Ministry of Internal Affairs of Russian Federation
🇷🇺Moscow, Russian Federation
Moscow Research Institute of Oncology P.A. Herzen
🇷🇺Moscow, Russian Federation
National Cancer Centre Singapore
🇸🇬Singapore, Singapore
Onkologicky Ustav sv. Alzbety
🇸🇰Bratislava, Slovakia
City Clinical Oncology Dispensary
🇷🇺St. Petersburg, Russian Federation
Narodny Onkologicky ustav
🇸🇰Bratislava, Slovakia
Nemocnica s poliklinikou Zilina
🇸🇰Zilina, Slovakia
Hospital Clinico Universitario Virgen de La Victoria
🇪🇸Malaga, Spain
Universitetssjukhuset, Onkologiska kliniken
🇸🇪Linkoping, Sweden
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
Onkologkliniken
🇸🇪Vaxjo, Sweden
Chang Gung Medical Foundation-Kaohsiung Branch
🇨🇳Kaohsiung Hsien, Taiwan
Department of Oncology, National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Royal Marsden Hospital
🇬🇧London, England, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, Middlesex, United Kingdom
University of Birmingham, CRUK Institute for Cancer Studies
🇬🇧Birmingham, United Kingdom
Royal Bournemouth & Poole Hospitals
🇬🇧Bournemouth, United Kingdom
Bristol Haematology and Oncology Centre
🇬🇧Bristol, United Kingdom
Addenbrooke's Hospital
🇬🇧Cambridge, United Kingdom
The Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Department of Medical Oncology, St. Bartholomew's Hospital
🇬🇧London, United Kingdom
University Department of Medical Oncology/Oxford Cancer Centre
🇬🇧Oxford, United Kingdom
Royal Marsden Hospital NHS Foundation Trust
🇬🇧Surrey, United Kingdom
Peachtree Hematology-Oncology Consultants, P.C.
🇺🇸Atlanta, Georgia, United States
Loyola University Chicago Cardinal Bernardin Cancer Center
🇺🇸Maywood, Illinois, United States
Florida Cancer Specialists
🇺🇸Venice, Florida, United States
Brian LeBerthon, MD, A Medical Corporation
🇺🇸West Covina, California, United States
The Cancer Center at Hackensack University Medical Center - The Hillcrest Building
🇺🇸Hackensack, New Jersey, United States
UCLA
🇺🇸Los Angeles, California, United States
Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
🇺🇸Columbus, Ohio, United States
Chattanooga Oncology and Hematology Associates, PC
🇺🇸Chattanooga, Tennessee, United States
Albermarie Hospitals
🇺🇸Elizabeth City, North Carolina, United States
Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc.
🇺🇸Oswego, New York, United States
Yamagata University Hospital
🇯🇵Yamagata, Japan
Raleigh Hematology Oncology Associates, P.C.
🇺🇸Raleigh, North Carolina, United States
Monarch
🇺🇸Mayfield Heights, Ohio, United States
Chattanooga Oncology Hematology Associates P.C.
🇺🇸Chattanooga, Tennessee, United States
Investigational Products Center (IPC)
🇺🇸Fort Worth, Texas, United States
Fundacao Pio XII Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin
🇩🇪Berlin, Germany
Ludwig-Maximilians-Universitaet Muenchen, Klinikum Grosshadern Urologische Klinik und Poliklinik
🇩🇪Muenchen, Germany
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
Pracownia Tomografii Komputerowej
🇵🇱Poznan, Poland
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Oncology Department
🇮🇪Dublin 24, Ireland
Christian Medical College & Hospital
🇮🇳Ludhiana, Punjab, India
Dept. of Medical Oncology, Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Texas Oncology - Central Midtown
🇺🇸Austin, Texas, United States
Texas Oncology - Austin Northwest
🇺🇸Austin, Texas, United States
M.D. Anderson Cancer Center Orlando
🇺🇸Orlando, Florida, United States
Orlando Regional Medical Center
🇺🇸Orlando, Florida, United States
Texas Oncology - Austin Central
🇺🇸Austin, Texas, United States
Texas Oncology - South Austin
🇺🇸Austin, Texas, United States
Texas Oncolgoy - Austin North
🇺🇸Austin, Texas, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Texas Oncology - Austin Midtown
🇺🇸Austin, Texas, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States